Monday, 16 Dec 2019

PsA/SpA

Datesort ascending Type Title Save
05 Dec 2019 News Secukinumab Improves Enthesitis
03 Dec 2019 Social RT @RWCSmtg: Filgotinib in AS #rheumatology https://t.co/vTsPjoogHv
03 Dec 2019 Social Spinal/SI MRI in the gen. population finds a high frequency of inflammatory and fatty MRI lesions suggestive of axSpA. MRI done in 793 volunteers < 45 yrs (49% males, 8.4% B27+). SI tJ Bone marrow edema in 17%, Vertebra BME 27% & fatty lesions in 81% https://t.co/XOzyWCyLyC
03 Dec 2019 News Spondyloarthritis Affects Pregnancy Outcomes
30 Nov 2019 Social Guselkumab, anti-IL23 in PsA Ph3 DISCOVER-1 trial in bio-naive or 30% prior TNFi = Effective at Wk 24 Safety same as with psoriasis trials. No Tb signal, No IBD signal. #ACR19 Abst0807 @_connectedcare https://t.co/d7hrn8VQO8
29 Nov 2019 Social Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/45Vahy36g7 #ACR19 @uptoTate abs#2881
29 Nov 2019 Social RT @JointMD: Panel Presentation: What’s New in Psoriatic Arthritis. So honored to join my colleagues Alexis Ogdie, Jose Scher, and Jessie W…
27 Nov 2019 Social #ACR19 ABST #1590 -3 RCTs show anti-TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials @DrPetryna
27 Nov 2019 News IL-17 Inhibitors In Non-Radiographic Axial SpA
26 Nov 2019 Social #ACR19 ABST #1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/S1WQDRFqTv https://t.co/oEKTnwUvJP
26 Nov 2019 Social #ACR19 abst #2476 Retrospective 2000-18 cohort study on side effects of MTX &TNFi in PSA vs RA: more side effects reported in MTX-PSA (42-46%) compared to MTX-RA pts (26-30%) or PsA or RA pts initiating a TNFi (20-25% of RA and 22-27% of PsA) @DrPetryna https://t.co/Eo3zwDgJMr https://t.co/eaq1gfD1eX
26 Nov 2019 Social #ACR19 ABS# 1481 Corrona PsA/SpA Registy: real-world use of COMBINATION Apremilast + biologics happens mostly in pts who received prior biologic therapy & pts not able to achieve MDA. @DrPetryna https://t.co/7OdLBalnPZ
21 Nov 2019 News Psoriatic Arthritis at ACR 2019
20 Nov 2019 Social @uptoTate PLENARY: COAST-X: IXE met ASAS 40 and all secondary endpoints in nr-axSpA vs PBO. https://t.co/mfTTMaCgWg #ACR19 Abst #2729 https://t.co/qaEi39JFPp
20 Nov 2019 Social @EBRheum RCT Tildrakizumab (IL23i) in Psoriatic Arthritis; Beats PLBO for ACR20 (NNT~4), ACR50 (NNT~4), and pt global (NNT~3 for 50% improvement) Very well tolerated (NNH>50, any adverse event). Exciting new tx! Need comparison RCT vs TNF/IL17i Abst#1821 https://t.co/b2yLF2YUSE https://t.co/2KW1Xo1lP9
20 Nov 2019 ACR Video Panel Presentation: Psoriatic Arthritis
20 Nov 2019 ACR Video New Treatments for Axial Spondyloarthritis: Dr. Antoni Chan
20 Nov 2019 ACR Video Comparison of Ixekizumab and Adalimumab in PsA: Dr. Olga Petryna
20 Nov 2019 ACR Video Ixekizimab Withdrawal in PSA: Dr. Eric Ruderman
20 Nov 2019 ACR Video Pearls for Evaluating PsA Patients: Dr. Guillermo Valenzuela